Literature DB >> 7534042

Immunohistochemical analysis of Bcl-2 protein regulation in cutaneous melanoma.

V A Tron1, S Krajewski, H Klein-Parker, G Li, V C Ho, J C Reed.   

Abstract

Cutaneous melanoma is becoming increasingly common. Genetic and environmental factors are thought to play a role in its pathogenesis. We have previously shown that normal human melanocytes strongly express the oncoprotein, Bcl-2. To determine the role of Bcl-2 in melanocytic tumors, we studied human benign nevi and melanomas for expression of Bcl-2 protein using immunohistochemistry. Our results show that benign melanocytes from 3 of 4 normal skin biopsies and 5 of 7 common acquired nevi strongly express Bcl-2. Conversely, only 3 of 23 primary cutaneous melanomas and 3 of 9 metastatic melanomas showed strong staining in comparison with melanocytes from normal skin and common acquired nevi (chi 2, P = 0.0021). Interestingly, 0 of 6 dysplastic nevi, a precursor of melanoma, demonstrated strong staining as compared with melanocytes and nevi (8 of 11; chi 2, P = 0.02), but similar expression to that of melanoma (6 of 32; chi 2, P = 0.6). We conclude that Bcl-2 expression decreases in malignant melanoma and suggest that this may be related to the autonomous growth characteristics of malignant melanoma.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7534042      PMCID: PMC1869164     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  50 in total

1.  Bcl-2 functions in an antioxidant pathway to prevent apoptosis.

Authors:  D M Hockenbery; Z N Oltvai; X M Yin; C L Milliman; S J Korsmeyer
Journal:  Cell       Date:  1993-10-22       Impact factor: 41.582

2.  Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death.

Authors:  Z N Oltvai; C L Milliman; S J Korsmeyer
Journal:  Cell       Date:  1993-08-27       Impact factor: 41.582

3.  Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo.

Authors:  T Miyashita; S Krajewski; M Krajewska; H G Wang; H K Lin; D A Liebermann; B Hoffman; J C Reed
Journal:  Oncogene       Date:  1994-06       Impact factor: 9.867

4.  Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair.

Authors:  D J Veis; C M Sorenson; J R Shutter; S J Korsmeyer
Journal:  Cell       Date:  1993-10-22       Impact factor: 41.582

5.  Bcl-2 inhibition of neural death: decreased generation of reactive oxygen species.

Authors:  D J Kane; T A Sarafian; R Anton; H Hahn; E B Gralla; J S Valentine; T Ord; D E Bredesen
Journal:  Science       Date:  1993-11-19       Impact factor: 47.728

6.  bcl-2 protein in non-small-cell lung carcinoma.

Authors:  F Pezzella; H Turley; I Kuzu; M F Tungekar; M S Dunnill; C B Pierce; A Harris; K C Gatter; D Y Mason
Journal:  N Engl J Med       Date:  1993-09-02       Impact factor: 91.245

7.  Expression of the apoptosis-suppressing protein bcl-2, in neuroblastoma is associated with unfavorable histology and N-myc amplification.

Authors:  V P Castle; K P Heidelberger; J Bromberg; X Ou; M Dole; G Nuñez
Journal:  Am J Pathol       Date:  1993-12       Impact factor: 4.307

8.  The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients.

Authors:  R Silvestrini; S Veneroni; M G Daidone; E Benini; P Boracchi; M Mezzetti; G Di Fronzo; F Rilke; U Veronesi
Journal:  J Natl Cancer Inst       Date:  1994-04-06       Impact factor: 13.506

Review 9.  Bcl-2 and the regulation of programmed cell death.

Authors:  J C Reed
Journal:  J Cell Biol       Date:  1994-01       Impact factor: 10.539

10.  bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer.

Authors:  R D Leek; L Kaklamanis; F Pezzella; K C Gatter; A L Harris
Journal:  Br J Cancer       Date:  1994-01       Impact factor: 7.640

View more
  15 in total

1.  Apoptosis: A Current Molecular Analysis.

Authors:  Dean G Tang; Arthur T Porter
Journal:  Pathol Oncol Res       Date:  1996       Impact factor: 3.201

Review 2.  Melanoma: from mutations to medicine.

Authors:  Hensin Tsao; Lynda Chin; Levi A Garraway; David E Fisher
Journal:  Genes Dev       Date:  2012-06-01       Impact factor: 11.361

3.  Bcl-2 immunoreactivity in prostate tumorigenesis in relation to prostatic intraepithelial neoplasia, grade, hormonal status, metastatic growth and survival.

Authors:  P Stattin; J E Damber; L Karlberg; H Nordgren; A Bergh
Journal:  Urol Res       Date:  1996

4.  Low prevalence of Helicobacter pylori infection in patients with hamartomatous fundic polyps.

Authors:  N Sakai; M Tatsuta; R Hirasawa; H Iishi; M Baba; Y Yokota; F Ikeda
Journal:  Dig Dis Sci       Date:  1998-04       Impact factor: 3.199

5.  Expression of Bcl-2, Melan A and HMB-45 in Dysplastic Nevi.

Authors:  Oana Maria Patrascu; Mariana Costache; Adrian Vasile Dumitru; Corina Nicoleta Mehotin; Maria Sajin; Anca Mihaela Lazaroiu
Journal:  Maedica (Bucur)       Date:  2016-03

6.  c-myc, p53, and Bcl-2 expression and clinical outcome in uveal melanoma.

Authors:  J S Chana; G D Wilson; I A Cree; R A Alexander; N Myatt; M Neale; A J Foss; J L Hungerford
Journal:  Br J Ophthalmol       Date:  1999-01       Impact factor: 4.638

7.  The dysplastic nevus: from historical perspective to management in the modern era: part II. Molecular aspects and clinical management.

Authors:  Keith Duffy; Douglas Grossman
Journal:  J Am Acad Dermatol       Date:  2012-07       Impact factor: 11.527

8.  Analysis of Bcl-2 protein expression in choroidal melanomas.

Authors:  M R Hussein
Journal:  J Clin Pathol       Date:  2005-05       Impact factor: 3.411

9.  Predicting transition from oral pre-malignancy to malignancy via Bcl-2 immuno-expression: Evidence and lacunae.

Authors:  Ruby Dwivedi; Shaleen Chandra; Divya Mehrotra; Vineet Raj; Rahul Pandey
Journal:  J Oral Biol Craniofac Res       Date:  2020-07-19

10.  The role of Bcl-2 family members in the progression of cutaneous melanoma.

Authors:  Jason A Bush; Gang Li
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.